Ligand Partner Novartis Gets Key E.U. Approval: Roth Capital Likes It
April 07, 2016 at 09:46 AM EDT
The European Commission [EC] has expanded the label for Revolade [Promacta], developed by Ligand Pharmaceuticals Inc. (NASDAQ: LGND) ...